Drug Trial Radar · NCT06775483
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance: a Phase II Clinical Study
Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
220
Planned (sponsor's estimate)
Start
Jan 17, 2025
Primary completion
Jun 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.The study is divided into two parts. The main objective of part I is to assess the efficacy and safety of JSKN016 in selected subjects with advanced non-small cell lung cancer. The main objective of part II is to compare the efficacy of JSKN016 and docetaxel in subjects with advanced non-small cell lung cancer.
Conditions
- Advanced Non-small Cell Lung Cancer
Interventions
JSKN016Drug
Administered intravenously according to protocol.
DocetaxelDrug
Administered intravenously according to protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR assessed by the investigator per RECIST v1.1Time frame: Up to 24months
- Safety reflected by AETime frame: Up to 24months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.